Exicure, Inc.

XCUR

Healthcare|Biotechnology|US

$0.95

+0.06 (+6.71%)

DCF Value

$0.35

Cash / Share

$0.27

Analyst Consensus

Buy6 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

Consensus Target

$12.00

Implied Upside

+1163.4%

Low Target

$12.00

High Target

$12.00

Price Target Trend

Last Month

—

0 targets

Last Quarter

—

0 targets

Last Year

—

0 targets

All Time

$12.00

1 target · +1163% vs price

Rating Trend

Dec 23

1 buy · 0 hold · 0 sell

Jan 24

1 buy · 0 hold · 0 sell

Feb 24

1 buy · 0 hold · 0 sell

Mar 24

1 buy · 0 hold · 0 sell

Apr 24

1 buy · 0 hold · 0 sell

May 24

1 buy · 0 hold · 0 sell

Jun 24

1 buy · 1 hold · 0 sell

Jul 24

1 buy · 1 hold · 0 sell

Aug 24

1 buy · 1 hold · 0 sell

Sep 24

1 buy · 1 hold · 0 sell

Oct 24

1 buy · 1 hold · 0 sell

Nov 24

1 buy · 0 hold · 0 sell

Recent Price Targets

Date	Firm	Analyst	Target	Price Then	Source
Jan 26, 2022	Chardan Capital	Keay Nakae	$0.40(-92%)	$4.94	Pulse 2.0

Recent Rating Actions

Firm	Action	Rating	Date
Chardan Capital	maintain	Neutral	Aug 16, 2022
Chardan Capital	downgrade	Buy →Neutral	Dec 13, 2021
Chardan Capital	maintain	Buy	Nov 23, 2021
HC Wainwright & Co.	maintain	Buy	May 17, 2021
BMO Capital	maintain	Outperform	Dec 18, 2020
Chardan Capital	maintain	Buy	Sep 17, 2020
Guggenheim	maintain	Buy	Nov 20, 2019
H.C. Wainwright	maintain	Buy	Nov 6, 2019
Chardan Capital	maintain	Buy	Mar 26, 2019
Ladenburg Thalmann	maintain	Buy	Jul 11, 2018

Earnings History

Next report: Nov 12, 2026 · EPS est. $-18.60

Report Date	EPS Actual	EPS Est.	Revenue Actual	Revenue Est.
Aug 14, 2026	$-0.18	$-0.19	—	$1.6M
May 29, 2026	$-0.29	$-0.95	—	$3.9M
Mar 25, 2026	$-0.46	$-0.95	$21.8M	$3.9M
Nov 7, 2025	$-0.39	$-4.50	$2.0M	$3.9M
Aug 8, 2025	$-0.41	$-6.00	$2.5M	$4.1M
Jun 27, 2025	$-0.45	$-10.50	$2.6M	$4.3M
Mar 18, 2025	$-22.50	$-21.00	$2.1M	$3.5M
Nov 14, 2024	$-40.50	$-13.88	-$3.7M	$7.0M

News

Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR)

Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Risk and Volatility Shattuck Labs has a beta

Oct 16, 2026defenseworld.net

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Sep 16, 2026globenewswire.com